Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

Abstract

Quiz Ref ID Genotype-directed targeted therapy is the standard of care for patients with advanced non–small cell lung cancer (NSCLC).¹ However, there are currently no targeted therapies specifically approved for patients with lung cancers related to a mutation in the v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS; OMIM:190070) gene, which are detected in approximately 25% of lung adenocarcinoma patients.² Such patients have a worse prognosis and may derive less clinical benefit from chemotherapy than the overall population of patients with NSCLC.^3-5